newsfilter
← Latest News
PR Newswire·

Halozyme Appoints Dannielle Appelhans to its Board of Directors

HALO
  • Halozyme Therapeutics, Inc. elected Dannielle Appelhans to its Board of Directors on August 18, 2026.
  • Appelhans possesses over 20 years of executive leadership experience in biotechnology, pharmaceuticals, operations, manufacturing, & supply chain management.
  • She currently serves as President & CEO of COUR Pharmaceuticals, where she negotiated a strategic collaboration with Genentech valued up to $1 billion.
  • Her prior roles include CEO of Rubius Therapeutics, Inc., Senior Vice President & Chief Technical Officer of Novartis Gene Therapies, & Senior Vice President of Global Head of Supply Chain Management.
  • CEO Dr. Helen Torley stated Appelhans operational expertise aligns with Halozyme's strategy to scale ENHANZE, advance Hypercon, & develop Surf Bio technologies.
  • Appelhans holds a Master of Science in mechanical engineering, an MBA from MIT Sloan, & a Bachelor of Science in mechanical engineering from the University of Michigan.
  • Halozyme's ENHANZE platform facilitates subcutaneous delivery for ten commercialized products across over 100 global markets.
  • The company expanded its portfolio with Hypercon™ & Surf Bio hyperconcentration technologies to reduce injection volumes & enable home administration.
  • Halozyme develops drug-device combination products using auto-injector technologies & markets proprietary products Hylenex® & XYOSTED®.
  • The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ; Minnetonka, MN; & Boston, MA.